RE:RE:RE:RE:update ...To date, volume suggests that not many holders are running for the hills yet. OncoQuest will have money or at least equity from OQP which means that if the assets are not liquidated and and Phase III is a commercial success it should see some returns in valuation from OQP, no?
And its one of the four "Technology/equity investment" ..Also looking at the BOD it does not strike me that this company is ready to fold the tent yet. Are they?
https://www.questpharmatech.com/leadership/
And the issuance of 1.5M share at $0.23 cents might suggest that there is expectations for a higher price sometimes in the future?
Then there's this but not sure to which extent this is Biolcentrant (0-100%) or not.
Mutant EGF - Wound Healing Technology
Quest is also developing products utilizing proprietary transdermal delivery technologies with a
focus on dermatology and wound healing applications. This patented mutant EGF wound healing technology was invented by Dr. Jennifer Cochran, associate professor of bioengineering at Stanford University, and is jointly owned by Stanford University and Massachusetts Institute of Technology. This new class of engineered EGF molecules have about 30 times more receptorbinding affinity than natural EGF and are protected by two U.S. patents. The technology can also be combined with Quest’s SP Technology to further enhance its effectiveness. Quest has an exclusive worldwide license from Stanford University to develop and commercialize this patented EGF wound healing technology.
One thing is sure, QPT could do some more work in communicating its value proposition now.
As in what is next for them? More importantly how will they plan to use the cash?
Bio-tech tend to be secretive but a quick blurb will help.
PS. Doubt that not many investors are here for a small one time dividend.